Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature

Current Gastroenterology Reports
Paul Y Kwo, Maaz B Badshah

Abstract

The addition of the first direct-acting antiviral agents, the NS3 protease inhibitors boceprevir or telaprevir, to peg interferon and ribavirin was a major advance in the treatment of genotype 1 hepatitis C individuals with sustained virological response (SVR) rates of 63-75 %. Those who did not achieve SVR had high rates of resistance-associated variants against NS3 protease domain. Retreatment options for those who have failed first-generation protease inhibitors generally are guided by retreatment with direct-acting antiviral agents from other classes. Phase 2 and phase 3 data have demonstrated that retreatment with 12-24 weeks of a NS5B inhibitor (sofosbuvir) in combination with a NS5a inhibitor (daclatasvir or ledipasvir) with or without ribavirin can achieve SVR at high rates comparable to treatment-naive individuals.

References

Nov 30, 1989·The New England Journal of Medicine·G L DavisUNKNOWN Hepatitis Interventional Therapy Group
Feb 1, 1995·Seminars in Liver Disease·J BukhR H Purcell
Jun 4, 1999·The Journal of General Virology·A K GhoshR B Ray
Jul 9, 2002·Oncogene·Keng-Hsin LanShou-Dong Lee
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Aug 20, 2003·International Journal of Cancer. Journal International Du Cancer·Yih-Lin ChungSang-Hue Yen
Apr 2, 2004·Gastroenterology·Mitchell L ShiffmanUNKNOWN Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group
Jun 9, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Lennox J JeffersK Rajender Reddy
Dec 16, 2004·JAMA : the Journal of the American Medical Association·Fabrice CarratUNKNOWN ANRS HCO2 RIBAVIC Study Team
Aug 19, 2005·Nature·Jordan J Feld, Jay H Hoofnagle
Aug 27, 2005·The Lancet Infectious Diseases·Colin W ShepardMiriam J Alter
Apr 15, 2006·International Journal of Medical Sciences·John Hoefs, Vikramjit S Aulakh
May 17, 2006·Annals of Internal Medicine·Gregory L ArmstrongMiriam J Alter
Jun 22, 2006·Infectious Disorders Drug Targets·Uwe Koch, Frank Narjes
Jun 7, 2007·World Journal of Gastroenterology : WJG·Miriam J Alter
Dec 1, 2007·Nature Reviews. Drug Discovery·Michael P MannsMichael Houghton
Dec 17, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Norman M KnetemanMarc Collett
Jul 25, 2009·The New England Journal of Medicine·John G McHutchisonUNKNOWN IDEAL Study Team
Sep 15, 2009·Nature Genetics·Vijayaprakash SuppiahJacob George
Dec 17, 2009·Gastroenterology·Christoph Sarrazin, Stefan Zeuzem
Feb 24, 2010·Antimicrobial Agents and Chemotherapy·Oliver LenzKenneth A Simmen
Apr 9, 2010·The New England Journal of Medicine·John G McHutchisonUNKNOWN PROVE3 Study Team
Jun 30, 2010·Antimicrobial Agents and Chemotherapy·Robert A FridellMin Gao
Oct 21, 2010·Seminars in Liver Disease·Marion Poenisch, Ralf Bartenschlager
Nov 19, 2010·Proceedings of the National Academy of Sciences of the United States of America·Keith P RomanoCelia A Schiffer
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators
Apr 1, 2011·The New England Journal of Medicine·Bruce R BaconUNKNOWN HCV RESPOND-2 Investigators
Apr 14, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Frank WagnerJennifer L Hammond
Jun 24, 2011·The New England Journal of Medicine·Ira M JacobsonUNKNOWN ADVANCE Study Team
Jun 24, 2011·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN REALIZE Study Team
Sep 8, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marc G GhanyUNKNOWN American Association for Study of Liver Diseases

❮ Previous
Next ❯

Citations

Dec 16, 2017·Current Treatment Options in Infectious Diseases·Autumn ZuckermanSusanna Naggie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.